{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:39:28Z","timestamp":1792787968464,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2013970"],"award-info":[{"award-number":["2013970"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.cmi.2026.06.019","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T23:25:31Z","timestamp":1782343531000},"page":"1864-1872","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Persistent and pathogen-specific infection risk during long-term survivorship after CD19 chimeric antigen receptor T-cell therapy: an Australian multicentre cohort study"],"prefix":"10.1016","volume":"32","author":[{"given":"Gemma K.","family":"Reynolds","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Dowling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safia","family":"Belbachir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilu","family":"Perera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Vanguru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin W.","family":"Teh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ann","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Barraclough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine S.","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Joy","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea S.","family":"Henden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin A.","family":"Thursky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica A.","family":"Slavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2026.06.019_bib1","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas Dos Santos","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2026.06.019_bib2","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/bloodadvances.2023011767","article-title":"Applying the EHA\/EBMT grading for ICAHT after CAR-T: Comparative incidence and association with infections and mortality","volume":"8","author":"Rejeski","year":"2024","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"10.1016\/j.cmi.2026.06.019_bib3","article-title":"Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies","volume":"25","author":"Kampouri","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.cmi.2026.06.019_bib4","doi-asserted-by":"crossref","first-page":"5460","DOI":"10.1182\/bloodadvances.2025016141","article-title":"Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: Real-world analysis from CIBMTR","volume":"9","author":"Wudhikarn","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.cmi.2026.06.019_bib5","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jtct.2024.07.018","article-title":"Best practice considerations by The American Society of Transplant and Cellular Therapy: Infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies","volume":"30","author":"Shahid","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.cmi.2026.06.019_bib6","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1182\/bloodadvances.2022007474","article-title":"Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma","volume":"6","author":"Little","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.cmi.2026.06.019_bib7","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: A model for CAR T-cell\u2013related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2026.06.019_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.cmi.2026.06.019_bib9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jtct.2024.10.010","article-title":"Shift from widespread to tailored antifungal prophylaxis in lymphoma patients treated with CD19 CAR T cell therapy: Results from a large retrospective cohort","volume":"31","author":"Melica","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.cmi.2026.06.019_bib10","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/S1473-3099(23)00377-8","article-title":"Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients","volume":"24","author":"Teh","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2026.06.019_bib11","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.06.019_bib12","unstructured":"Device-Associated Module 4: Bloodstream Infection Event (Central Line-Associated Bloodstream Infection and Non-central Line Associated Bloodstream Infection). Centers for Disease Control and Prevention (CDC). https:\/\/www.cdc.gov\/nhsn\/pdfs\/pscmanual\/4psc_clabscurrent.pdf. [Accessed 24 November 2025]."},{"key":"10.1016\/j.cmi.2026.06.019_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2025.07.022","article-title":"Opportunities to improve antibiotic stewardship, and identification of blood biomarkers associated with bacteremia following CAR-T cell therapy","volume":"31","author":"Ng","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.cmi.2026.06.019_bib14","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.cmi.2024.11.008","article-title":"Timeline and outcomes of viral and fungal infections after Chimeric Antigen Receptor (CAR) T-cell therapy: A large database analysis","volume":"31","author":"Sassine","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2026.06.019_bib15","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.cmi.2025.10.005","article-title":"Invasive fungal infections after CD19 chimeric antigen receptor T-cell therapy for B-cell lymphoma: A lymphoma study association study from the DESCAR-T (Dispositif d\u2019Enregistrement et Suivi des patients trait\u00e9s par CAR-T cells) registry","volume":"32","author":"Bouvier","year":"2026","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2026.06.019_bib16","doi-asserted-by":"crossref","first-page":"6380","DOI":"10.1182\/bloodadvances.2025017081","article-title":"Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe","volume":"9","author":"Pennings","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.cmi.2026.06.019_bib17","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1182\/hematology.2024000534","article-title":"Late complications and long-term care of adult CAR T-cell patients","volume":"2024","author":"Bishop","year":"2024","journal-title":"Hematol Am Soc Hematol Educ Prog"},{"issue":"Suppl 1","key":"10.1016\/j.cmi.2026.06.019_bib18","article-title":"Respiratory viral infections are a significant cause of morbidity during long-term follow-up after CAR T cell therapy: Analysis of 445 episodes","volume":"146","author":"Einarsdottir","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2026.06.019_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.12.616","article-title":"Incidence and characteristics of respiratory viral infections after CAR T-cell therapy","volume":"30","author":"Weiss","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.cmi.2026.06.019_bib20","series-title":"Medical Services Advisory Committee (MSAC) public summary document application no. 1722.1 \u2013 Axicabtagene ciloleucel (Yescarta\u00ae) for relapsed or refractory large B-cell lymphoma; 2024","year":"2024"},{"key":"10.1016\/j.cmi.2026.06.019_bib21","article-title":"The reduced incidence of respiratory viral infections in transplant recipients during the COVID-19 pandemic \u2013 A retrospective observational cross-sectional analysis of admissions to a tertiary haematology unit","volume":"20","author":"Farooq","year":"2023","journal-title":"Clin Infect Pract"},{"key":"10.1016\/j.cmi.2026.06.019_bib22","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2020002732","article-title":"Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma","volume":"5","author":"Baird","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.cmi.2026.06.019_bib23","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","article-title":"Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy","volume":"57","author":"Wudhikarn","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl 1","key":"10.1016\/j.cmi.2026.06.019_bib24","article-title":"P-1013. Incidence and risk factors for fungal infection after CD19-targeted Chimeric Antigen Receptor T cell therapy for non-Hodgkin lymphoma","volume":"12","author":"Gaulin","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2026.06.019_bib25","series-title":"The EBMT\/EHA CAR-T cell handbook","author":"Kr\u00f6ger","year":"2022"},{"key":"10.1016\/j.cmi.2026.06.019_bib26","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1002\/hem3.29","article-title":"High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma","volume":"8","author":"O'Reilly","year":"2024","journal-title":"Hemasphere"},{"key":"10.1016\/j.cmi.2026.06.019_bib27","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41408-024-01043-5","article-title":"Comparison of infectious complications with BCMA-directed therapies in multiple myeloma","volume":"14","author":"Nath","year":"2024","journal-title":"Blood Cancer J"},{"issue":"Suppl 1","key":"10.1016\/j.cmi.2026.06.019_bib28","doi-asserted-by":"crossref","first-page":"10073","DOI":"10.1182\/blood-2022-163733","article-title":"Infections and severe hypogammaglobulinemia in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"140","author":"Lancman","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2026.06.019_bib29","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/cid\/ciad708","article-title":"Cytomegalovirus (CMV) reactivation and CMV-specific cell-mediated immunity after Chimeric Antigen Receptor T-cell therapy","volume":"78","author":"Kampouri","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.cmi.2026.06.019_bib30","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1182\/blood-2022-167908","article-title":"Cytomegalovirus (CMV) reactivation within in the first year after Chimeric Antigen Receptor (CAR) T cell therapy: Experience from the first two years at a major cancer center","volume":"140","author":"Khawaja","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2026.06.019_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104134","article-title":"Infections in haematology patients treated with CAR-T therapies: A systematic review and meta-analysis","volume":"192","author":"Reynolds","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.cmi.2026.06.019_bib32","doi-asserted-by":"crossref","first-page":"851.e1","DOI":"10.1016\/j.jtct.2022.09.007","article-title":"Impact of cytomegalovirus replication in patients with aggressive B cell lymphoma treated with Chimeric Antigen Receptor T Cell therapy","volume":"28","author":"M\u00e1rquez-Algaba","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.cmi.2026.06.019_bib33","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1182\/blood.2025029057","article-title":"Human herpesvirus 6 viremia and encephalitis in CAR T-cell recipients","volume":"146","author":"Isaac","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2026.06.019_bib34","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell\u2013associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26003319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26003319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:19:51Z","timestamp":1792725591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X26003319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1198743X26003319"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2026.06.019","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Persistent and pathogen-specific infection risk during long-term survivorship after CD19 chimeric antigen receptor T-cell therapy: an Australian multicentre cohort study","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2026.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}